Day: May 26, 2020

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public offering of $60 million of its shares of common stock. All of the shares will be offered by TransMedics. TransMedics also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15 percent of the number of shares sold in the offering.J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. Canaccord Genuity is acting as lead manager for the proposed offering.A shelf registration statement on Form S-3 relating to the securities being...

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported positive top-line results from its U.S. Pivotal OCS Liver PROTECT Trial. The trial achieved its primary clinical objectives by meeting both the primary and secondary effectiveness and safety endpoints.  For the primary effectiveness endpoint, the use of OCS Liver resulted in a significantly lower incidence of early allograft dysfunction (EAD) compared to control (17.3% OCS vs. 30.5% Control p=0.009) across both the donors after brain death (DBD) and donors after circulatory death (DCD) cohorts in the trial. EAD is the most common severe complication that occurs early after liver transplantation....

Or Yehuda, Israel, May 26, 2020 (GLOBE NEWSWIRE) — Magic Software Enterprises Ltd. (NASDAQ and TASE: MGIC), a global provider of end-to-end integration and application development platforms solutions and IT consulting services, announced today its financial results for the first quarter ended March 31, 2020.Financial Highlights for the First Quarter Ended March 31, 2020Revenues for the first quarter ended March 31, 2020 increased 19% to $85.2 million compared to $71.8 million in the same period last year.Operating income for the first quarter ended March 31, 2020 increased 4% to $8.7 million compared to $8.4 million in the same period last year.Non-GAAP operating income for the first quarter ended March 31, 2020 increased 9% to $11.0 million compared to $10.1 million in the same period last year.Net income attributable to Magic’s...

GOLETA, Calif., May 26, 2020 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, provided an update on the progress it is making with its partner, Teledyne Scientific & Imaging, in further validating the power of Resonant’s Infinite Synthesized Networks (ISN®) software platform by developing wide bandwidth, high frequency XBAR® filters with its fourth foundry for devices targeted at non-mobile applications.These all-acoustic XBAR filters fabricated by Teledyne Scientific are predicted to exhibit the best-in-class wide bandwidth and low insertion loss performance required for the worlds cutting edge 5G applications, without the need for lossy bandwidth-enhancing techniques, such as IPDs.“Our...

C. Keith Cargill Steps Down as President and Chief Executive Officer Larry L. Helm to Serve as Executive Chair, CEO and President Until a Permanent Successor Is NamedDALLAS, May 26, 2020 (GLOBE NEWSWIRE) — Texas Capital Bank, N.A., and its parent company Texas Capital Bancshares, Inc. (NASDAQ: TCBI), collectively referred to herein as “Texas Capital,” today announced that C. Keith Cargill has stepped down as President and Chief Executive Officer and a member of the Board of Directors of both companies, effective immediately. Larry L. Helm, who has served as Chairman of the Texas Capital Bancshares Board since 2012, will serve as Executive Chair, CEO and President of both companies until a permanent successor has been named. Mr. Cargill will serve as Vice Chairman of both companies through the end of 2020 to help support a smooth...

MEMPHIS, Tenn., May 26, 2020 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $2.8 billion for its third quarter (12 weeks) ended May 9, 2020, a decrease of 0.1% from the third quarter of fiscal 2019 (12 weeks). “Prior to a discussion of our third quarter results, it is important to address the impact the COVID-19 crisis has had on our business.  While certain retailers closed their stores during this time, our stores remained open to service the motoring public.  First and foremost, the health, safety and well-being of our AutoZoners and customers remains our most important concern.  During these times our AutoZoners have made sure customers can safely and responsibly operate their vehicles and get back on the road.  To better serve our customers and promote health and safety, we initially reduced the hours...

– Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial –– Top Line Results of Pivotal CONNECT-FX Trial Expected Late in the Second Quarter of 2020 –DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the availability of a poster describing 116-week (two-year) data from the Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial of Zygel™ (CBD transdermal gel; ZYN002) in pediatric and adolescent patients with Fragile X syndrome (FXS). The data in the poster show that the statistically significant improvements from baseline that...

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m. ET. The conference is being held virtually from June 2-4, 2020.The live webcast will be available in the investor section of the company’s website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic...

VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (TSX-V: PGM, LSE: PUR) (“PureGold” or the “Company”) is pleased to announce that the Company has raised $12.3 million from the exercise of 14,465,000 share purchase warrants with a strike price of $0.85 (the “Warrants”), representing 100% of the Warrants that otherwise would have expired May 24, 2020.On closing of the recently announced private placement, PureGold will have approximately $101 million in cash, along with $US35M available in an undrawn credit facility. With approximately $150 million available in funding, and $86 million remaining on capital expenditure to complete our mine construction, the Company is in a uniquely solid financial position to be able to concurrently fund an aggressive exploration program.   Commencing June 3rd this...

STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.“We are delighted to welcome Julie to the SpringWorks Board of Directors. She is a leading oncology drug developer whose experience will further strengthen our board and provide valuable insight as we advance our diversified pipeline of targeted oncology programs in rare oncology indications, multiple myeloma and metastatic solid tumors,” said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics.Dr. Hambleton, M.D. added, “I am impressed by the breadth and quality of targeted oncology programs...